Johnson Chemical Pharmaceutical Works (4747) reported revenue of NT$50.1 million for Oct 2026, -2.7% year on year and +2.2% from the previous month. Revenue for Jan–Oct 2026 was NT$492.4 million (+4.6% year on year).
In Oct 2026, it ranked No. 99 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$50.1 million | -2.7% | +2.2% |
| Sep 2026 | NT$49 million | +9.2% | +6.9% |
| Aug 2026 | NT$45.8 million | +1.1% | -15.9% |
| Jul 2026 | NT$54.5 million | +23.6% | +15.3% |
| Jun 2026 | NT$47.3 million | +2.2% | -10.0% |
| May 2026 | NT$52.5 million | +15.7% | +12.2% |
| Apr 2026 | NT$46.8 million | +0.5% | -7.2% |
| Mar 2026 | NT$50.4 million | +6.7% | +33.1% |
| Feb 2026 | NT$37.9 million | -6.6% | -35.1% |
| Jan 2026 | NT$58.4 million | -1.2% | +15.0% |
| Dec 2025 | NT$50.8 million | +7.6% | +5.0% |
| Nov 2025 | NT$48.3 million | -4.8% | -6.1% |
| Oct 2025 | NT$51.5 million | +3.2% | +14.8% |
| Sep 2025 | NT$44.8 million | -1.7% | -1.1% |
| Aug 2025 | NT$45.3 million | -23.1% | +2.8% |
| Jul 2025 | NT$44.1 million | -3.0% | -4.7% |
| Jun 2025 | NT$46.3 million | -12.4% | +1.9% |
| May 2025 | NT$45.4 million | -8.5% | -2.5% |
| Apr 2025 | NT$46.5 million | -3.0% | -1.4% |
| Mar 2025 | NT$47.2 million | -8.1% | +16.5% |
| Feb 2025 | NT$40.5 million | +1.2% | -31.4% |
| Jan 2025 | NT$59.1 million | -17.7% | +25.2% |
| Dec 2024 | NT$47.2 million | -6.6% | -7.1% |
| Nov 2024 | NT$50.8 million | -4.3% | +1.8% |
| Oct 2024 | NT$49.9 million | -2.5% | +9.3% |
Jan–Oct 2026 cumulative: NT$492.4 million (+4.6% YoY)
Other Biotech & Medical companies
Compare with peers: Johnson Chemical Pharmaceutical Works vs PEC / Johnson Chemical Pharmaceutical Works vs Lotus Pharm / Johnson Chemical Pharmaceutical Works vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16